Avant Diagnostics, Inc. (OTC: AVDX) is a medical technology company based on the completion of the human genome-sequencing project. Avant is developing specialized tests that are cutting edge in medical testing and its OvaDx Pre-Symptomatic Ovarian Cancer Screening Test is a leading breakthrough in commercializing these tests. At Avant Diagnostics, its approach is based on more than 10 years of research and development. Avant’s proteomic, which focus non-genetic and physiological traits, exploits the immune system for early detection of ovarian cancer. Avant’s advanced technology allows the company to reduce costs and increase its samples. For more information, visit the company’s website at www.avantdiagnostics.com